Head-to-head · Cost-Efficiency Index
Maves vs Peter MD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Maves
Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout.
Visit MavesPeter MD
Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost.
Visit Peter MDThe verdict
Maves takes it, leading the Cost-Efficiency Index 76 to 72. Maves (operated by parent company Homera Health) is a men's-health/performance-framed telehealth platform offering compounded semaglutide and tirzepatide plus sermorelin. Peter MD still earns a C — Someone who wants a single telehealth account to also cover TRT, hair loss, ED or NAD+ alongside a GLP-1 script, and who will read past the first-month price before budgeting the ongoing cost.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Maves.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Maves | Peter MD |
|---|---|---|
| Cost-Efficiency Index | 76/100 | 72/100 |
| Semaglutide / mo | $89/mo (starting dose, compounded) | $149/mo first-time (Level 1), $139/mo returning (Level 2) |
| Tirzepatide / mo | Not disclosed | $149 first month, then $249/mo billed quarterly |
| Semaglutide / yr (modeled) | $1,068 | $1,788 |
| Tirzepatide / yr (modeled) | — | $2,988 |
| Coverage | All 50 states | Varies by treatment — excluded in several states (marketing pages list AL/ID; the affiliate program's own disclosure is wider) |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #49 | #54 |
Maves
76/100Where the value is
- LegitScript badge displayed on the site
- Publishes the FDA compounded-medication disclaimer
- Low advertised semaglutide entry price ($89-99/mo range)
The tradeoffs
- The homepage shows two different numbers for the same starting semaglutide tier ($89/month vs $99 first month) with no reconciliation — the real ongoing price cannot be confirmed from the public site
- Tirzepatide is listed as an offering but no price is published anywhere reachable on the site, confirmed by direct search
Peter MD
72/100Where the value is
- Broadest cross-category catalog in this ranking under one account: TRT, ED, non-GLP-1 weight loss, GLP-1 (semaglutide/tirzepatide), men's hair loss and NAD+, plus sermorelin
- Physician-prescribed, nationwide telehealth brand operating since 2021 (Miami, FL HQ)
- Sermorelin ($585 for a 12-week supply, ~$195/mo) and NAD+ ($369 for an 8-10 week supply, ~$147-184/mo) sit in the same catalog as the GLP-1 line for anyone consolidating multiple scripts
The tradeoffs
- Tirzepatide's $149 first-month rate steps up to $249/mo billed quarterly — the number that matters for budgeting is the renewal price, not the headline
- Semaglutide pricing depends on tier: $149/mo first-time (Level 1) vs $139/mo returning (Level 2), with different total costs ($447 vs $834) over different supply windows, so the all-in cost is not a single number
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.